Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Lumretuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Lumretuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Lumretuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Lumretuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Lumretuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Lumretuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Lumretuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Lumretuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Lumretuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Lumretuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Lumretuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Lumretuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Lumretuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lumretuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lumretuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Lumretuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Lumretuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Lumretuzumab. |
| Equol | Equol may increase the thrombogenic activities of Lumretuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Lumretuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Lumretuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Lumretuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Lumretuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Lumretuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Lumretuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Lumretuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Lumretuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Lumretuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Lumretuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Lumretuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Lumretuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lumretuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Lumretuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Lumretuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Lumretuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lumretuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lumretuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Lumretuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lumretuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Lumretuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Lumretuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Lumretuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lumretuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumretuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Lumretuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lumretuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lumretuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Lumretuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lumretuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Lumretuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Lumretuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Lumretuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lumretuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lumretuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Lumretuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Lumretuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Lumretuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Lumretuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Lumretuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Lumretuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Lumretuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Lumretuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Lumretuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Lumretuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Lumretuzumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Lumretuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Lumretuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Lumretuzumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Lumretuzumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Lumretuzumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Lumretuzumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Lumretuzumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Lumretuzumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Lumretuzumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Lumretuzumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Lumretuzumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Lumretuzumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Lumretuzumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Lumretuzumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Lumretuzumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Lumretuzumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Lumretuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Lumretuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Lumretuzumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Lumretuzumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Lumretuzumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Lumretuzumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lumretuzumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Lumretuzumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Lumretuzumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Lumretuzumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Lumretuzumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Lumretuzumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Lumretuzumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Lumretuzumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Lumretuzumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Lumretuzumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Lumretuzumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Lumretuzumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Lumretuzumab. |